Paper20071683
Prevalence and systemic risk factors for retinal vein occlusion in a general Japanese population: the Hisayama study.
Yasuda M and 7 others. Invest Ophthalmol Vis Sci, 2010. Cited by 84 papers, by iCite.
Cite this record
ConductScience Library. Prevalence and systemic risk factors for retinal vein occlusion in a general Japanese population: the Hisayama study. Papers, record 20071683. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20071683
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Prevalence and systemic risk factors for retinal vein occlusion in a general Japanese population: the Hisayama study.
- PubMed
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Asian People | Major topic |
| Retinal Vein Occlusion | Major topic |
| Adult | |
| Age Distribution | |
| Aged | |
| Aged, 80 and over | |
| Blood Glucose | |
| Blood Pressure | |
| Cross-Sectional Studies | |
| Female | |
| Hematocrit | |
| Humans | |
| Hypertension | |
| Japan | |
| Male | |
| Middle Aged | |
| Odds Ratio | |
| Prevalence | |
| Prospective Studies | |
| Risk Factors | |
| Sex Distribution |
Source PubMed
Cited by58
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 84 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42880818 | Non-inferiority study of the efficacy of ranibizumab BS compared with aflibercept in patients with macular oedema due to untreated branch retinal vein occlusion: REMEDY-BRVO study - study protocol. | BMJ Open Ophthalmol | 2026 | https://conductscience.org/library/papers/42880818 | PubMed |
| 42115364 | Increased prevalence of hearing loss and tinnitus in patients with retinal vein occlusion. | Sci Rep | 2026 | https://conductscience.org/library/papers/42115364 | PubMed |
| 42018115 | Branch retinal vein occlusion in Leber hereditary optic neuropathy with onset at age 50 years or older: frequency and clinical characteristics. | Jpn J Ophthalmol | 2026 | https://conductscience.org/library/papers/42018115 | PubMed |
| 41940529 | Associations of nutritional intake and body mass index with branch retinal vein occlusion: A cross-sectional study using data from a Korean national survey. | Sci Prog | 2026 | https://conductscience.org/library/papers/41940529 | PubMed |
| 41835289 | Optimal Treatment of Retinal Vein Occlusion: An Updated Canadian Review and Recommendations. | Clin Ophthalmol | 2026 | https://conductscience.org/library/papers/41835289 | PubMed |
| 41790764 | Hemodynamic instability and retinal vein occlusion in glaucoma: Comparative analysis of heart rate variability and choroidal perfusion. | PLoS One | 2026 | https://conductscience.org/library/papers/41790764 | PubMed |
| 41476123 | The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025). | Hypertens Res | 2026 | https://conductscience.org/library/papers/41476123 | PubMed |
| 41375850 | Development of an Algorithm to Assist in the Diagnosis of Combined Retinal Vein Occlusion and Glaucoma. | J Clin Med | 2025 | https://conductscience.org/library/papers/41375850 | PubMed |
| 40195975 | Risk factors of retinal vein occlusion in East Asia: a meta-analysis. | Front Ophthalmol (Lausanne) | 2025 | https://conductscience.org/library/papers/40195975 | PubMed |
| 39648855 | Causal association between glaucoma and risk of retinal vascular occlusion: a Mendelian randomization study. | J Int Med Res | 2024 | https://conductscience.org/library/papers/39648855 | PubMed |
| 39204083 | New Therapeutic Strategies in Retinal Vascular Diseases: A Lipid Target, Phosphatidylserine, and Annexin A5-A Future Theranostic Pairing in Ophthalmology. | Pharmaceuticals (Basel) | 2024 | https://conductscience.org/library/papers/39204083 | PubMed |
| 39132113 | Demographic profile, prevalence, pattern, and risk factors for retinal vein occlusion in Liberia: A retrospective study. | Oman J Ophthalmol | 2024 | https://conductscience.org/library/papers/39132113 | PubMed |
| 39105547 | Prevalence and risk factors of retinal vein occlusion in individuals with diabetes: The kailuan eye study. | Diab Vasc Dis Res | 2024 | https://conductscience.org/library/papers/39105547 | PubMed |
| 39043891 | Time to initiate anti-vascular endothelial growth factor therapy and visual outcome in central retinal vein occlusion. | Sci Rep | 2024 | https://conductscience.org/library/papers/39043891 | PubMed |
| 38409518 | Vision-related quality of life in patients with retinal vein occlusion. | Int Ophthalmol | 2024 | https://conductscience.org/library/papers/38409518 | PubMed |
| 38096214 | Maximum carotid intima-media thickness and NT-pro BNP in association with retinal vein occlusion. | PLoS One | 2023 | https://conductscience.org/library/papers/38096214 | PubMed |
| 37408057 | Are inner nuclear layer ischemic lesions hidden indicators of retinal vein occlusion risk? A case-control study. | Int J Retina Vitreous | 2023 | https://conductscience.org/library/papers/37408057 | PubMed |
| 37223029 | Mendelian randomization indicates a causal contribution of type 2 diabetes to retinal vein occlusion. | Front Endocrinol (Lausanne) | 2023 | https://conductscience.org/library/papers/37223029 | PubMed |
| 37091777 | Prevalence and risk factors of retinal vein occlusion in the United States: The National Health and Nutrition Examination Survey, 2005 to 2008. | Proc (Bayl Univ Med Cent) | 2023 | https://conductscience.org/library/papers/37091777 | PubMed |
| 37061579 | Novel superpixel method to visualize fundus blood flow resistivity in healthy adults. | Sci Rep | 2023 | https://conductscience.org/library/papers/37061579 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20071683
GET https://conductscience.org/api/papers/v1/20071683/cited_by?page=2